Bmi Korea Co., Ltd

Catholic University Industry Academic Cooperation Foundation

Koo Woo

Sung-Hee Lee

Yeong Jun Baik

Yeong-Jun Baik

Min-Kyoung Kim

Kyeong Woo Min

Choun-Ki Joo

Jun-Sub Choi

Sung Hee Lee

Ha-Na Kim

The present invention relates to a hemostatic composition and a method for preparing thereof, and more specifically, relates to a hemostatic composition comprising a cross-linked hyaluronic acid derivative matrix which is suitable to be used for hemostasis and a method of preparation of such a composition.

Hemostatic composition comprising cross-linked hyaluronic acid derivative matrix

The present invention refers to the injectable hyaluronic acid composition which is crosslinked viscoelastic hyaluronic acid gel comprising DNA fractions. More particularly, it refers to the injectable hyaluronic acid composition comprising a hyaluronic acid composition crosslinked in the basic conditions with the degree of crosslinking between 0.1 and 200%, which is mixed with the DNA fractions of 0.1 to 50 wt %. The DNA fractions are selected, for example, from polynucleotide (PN) and polydeoxyribonucleotide (PDRN). The composition used for cosmetic purposes or therapeutic purposes, have improved viscoelastic rheological properties and enzyme resistance.

Composition for injection of hyaluronic acid, containing hyaluronic acid derivative and DNA fraction, and use thereof

This invention relates to a stable hyaluronidase liquid formulation comprising a hyaluronidase and a stabilizer for hyaluronidase. In particular, the hyaluronidase has a purity of 95% or more and the specific activity of 70,000 IU/mg or more, and the stabilizer for hyaluronidase contains a buffering agent in order to provide pH of 4.0 to 6.0; 0.001 to 0.5 v/v % of a non-ionic surfactant; and 0.1 to 5 mM of a chelating agent or MgCl. The liquid formulation has advantages in that it stably maintains its activity for a long period of time and may be easily administered than the conventional formulations.

Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase

The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.

Composition for inhibiting after-cataract and method of preparing the same

Growing community of inventors

Gwacheon, South Korea

Koo Woo